Combining an investigational agent, cagrilintide (Novo Nordisk), with semaglutide, a glucagon-like peptide-1 (GLP-1) agonist, leads to greater weight loss than semaglutide alone in people with a body mass index (BMI) over 27 kg/m2, and the combination was well-tolerated, shows a phase 1 study.
The research was presented at the online ECO 2021 meeting by Lone Enebo, PhD, from Novo Nordisk, Denmark, and simultaneously published in The Lancet.
“Treatment with cagrilintide at all tested doses in combination with semaglutide 2.4 mg was generally well-tolerated with an acceptable safety profile,” say Enebo and coauthors, adding that no apparent difference was seen in the number of adverse events across treatment groups.
“The data support once-weekly dosing. The combination of cagrilintide 1.2, 2.4, or 4.5 mg plus semaglutide 2.4 mg led to greater weight loss compared with semaglutide 2.4 mg only.”
The once-weekly dosing regimen was associated with clinically meaningful weight loss of up to 17.1% of body weight without lifestyle interventions.
“These data support the further clinical development of cagrilintide and semaglutide 2.4 mg as a potential novel and effective combination therapy for weight management,” they add.
In an accompanying commentary, Sara Becerril, PhD candidate, and Gema Frühbeck, MD, from the University of Navarra, Pamplona, Spain, said: “Approved pharmacological treatment options [for overweight and obesity] are scarce and do not satisfactorily bridge the gap in efficacy between lifestyle behavioral changes and bariatric surgery to attain sustained long-term results.”
But they emphasize: “Because the study was designed for safety, the weight loss outcomes need to be analyzed with caution. No lifestyle intervention was prescribed to produce weight loss…Moreover, the protocol was amended to include the highest cagrilintide dose, which might have been data driven.”
Study Conducted in US
Semaglutide is currently approved at a dose of 1.0 mg injected subcutaneously once weekly for the treatment of type 2 diabetes, and as an oral agent for the same indication. It is being developed for chronic weight management at a dose of 2.4 mg injected subcutaneously once weekly. New drug applications are under review for the treatment of obesity by the US Food and Drug Administration, the European Medicines Agency, and other health agencies, with a decision on the US approval expected soon.
The STEP trials, which have been published in various journals over the past year, have established the efficacy and safety of semaglutide 2.4 mg to treat people with obesity.
For the current study, conducted in the United States, 96 individuals, of whom 95 were exposed to treatment, aged 18-55 years with a BMI of 27.0-39.9 kg/m² who were otherwise healthy were randomized to cagrilintide (0.16-2.4 mg, n = 12 in each group; 4.5 mg group, n = 11) or placebo (n = 24) in combination with semaglutide 2.4 mg. Mean age was 40.6 years, 59% of participants were men, and 54% were Black or African American.
The 20-week trial included a 16-week escalation period (where participants randomized to cagrilintide received progressively increasing doses up to the target dose levels) followed by a 4-week treatment period at target dose (there were six different target dose levels, one per cohort: 0.16, 0.3, 0.6, 1.2, 2.4, or 4.5 mg) and a 5-week follow-up. Participants, investigators, and sponsor were all masked.
The primary endpoint was number of treatment-emergent adverse events from baseline to follow-up (end of week 25).
No Clear Differences in Adverse Events Between Groups
Most adverse events reported were mild or moderate in severity, and there were no apparent differences between treatment groups: events were reported in 69/71 participants taking 0.16-4.5 mg cagrilintide and 23/24 on placebo.
Two severe adverse events were reported in two participants, one with cagrilintide 1.2 mg in combination with semaglutide 2.4 mg (viral meningitis), and one in the pooled placebo in combination with semaglutide 2.4 mg group (serum creatinine increase). Both the events were deemed unlikely to be related to study treatment.
The most common adverse events reported were gastrointestinal disorders in 77% of participants, most frequently nausea in 56%, vomiting in 24%, and dyspepsia in 28%. On placebo, 79% of participants experienced gastrointestinal events.
At week 20, mean percentage body weight reductions from baseline were greater with cagrilintide 1.2 mg (15.7%) and 2.4 mg (17.1%) than for pooled placebo (9.8%).
Cagrilintide 4.5 mg led to a mean weight reduction of 15.4% compared with 8.0% for placebo (both plus semaglutide).
“Mean body weight reductions in this trial were also greater than those found in 26 weeks with cagrilintide alone (up to 7.8% reduction in body weight relative to placebo with 4.5-mg dose),” add the authors, referring to previous research.
Phase 3 Trial Program With Cagrilintide Is Planned
Enebo and coauthors explain that cagrilintide is thought to affect food choices by targeting both homeostatic and hedonic regions of the brain to induce satiety.
“Although both semaglutide and cagrilintide [both] induce satiety, they operate in different regions of the brain, which might result in an additive effect on appetite regulation. Moreover, the potential for cagrilintide to affect food choices might contribute to the modification of eating behaviors, further improving treatment efficacy.”
“Our data support the further clinical development of this drug combination for weight management. A phase 3 trial program is now being planned to test cagrilintide in combination with semaglutide for weight management,” they conclude.
Enebo is an employee and shareholder at Novo Nordisk. Becerril and Frühbeck have reported receiving grants from the Salud Carlos III Health Institute, CIBEROBN, and are cofunded by the European Union.
ECO 2021. Session AD12.04. Presented May 13, 2021.
Lancet. Published online April 22, 2021. Abstract
Need Your Help Today. Your $1 can change life.